Renalytix publishes real-world data showing KidneyIntelX slows CKD progression and improves diabetes control

Renalytix plc

Study of 2,569 patients with Type 2 diabetes and DKD: KidneyIntelX deployment associated with slowed kidney function decline and improved A1C levels.
61% increase in preventative drug prescriptions among high-risk group; improved specialist referrals.
KidneyIntelX has Medicare, Medicaid, and Blue Cross coverage; FDA de novo authorization received June 2023.
27% of study cohort were Black patients; median age 68, BMI 30, 89% hypertension.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.